Merck

Last updated January 31, 2026

124

Innovation Areas

5,362

Inventors

Collaborations

Small molecule plasma kallikrein inhibitors: MerckRecent Research Landscape

Uncontrolled kinin-kallikrein pathway activation triggers life-threatening angioedema and vascular permeability. These molecular inhibitors modulate enzyme activity to prevent excessive inflammatory peptide release.

What technical problems is Merck addressing in Small molecule plasma kallikrein inhibitors?

Excessive vascular permeability

(7)evidences

Uncontrolled plasma kallikrein activity leads to pathological fluid leakage from blood vessels. Preventing this leakage mitigates tissue swelling and inflammatory damage.

Excessive vascular permeability

(2)evidences

Uncontrolled kinin-kallikrein pathway activation leads to pathological fluid leakage from blood vessels. Preventing this leakage mitigates tissue swelling and inflammatory damage in conditions like hereditary angioedema.